Advertisement announced that the U.S. Department of Health and Human Services (HHS) was recently shipped 6,383,000 tablets of FDA approved potassium iodide for protection against radiation in the event of a nuclear reactor accident. The balance of the total 14 million tablet solicitation by HHS, on behalf of the Nuclear Regulatory Commission (NRC), is scheduled for delivery by the end of 2014.

Limited Distribution
Distribution of the potassium iodide is limited to only a few tablets for each U.S. resident that lives within the NRC's 10-mile Emergency Planning Zone around U.S. nuclear reactors. However, the American Thyroid Association states "Potassium iodide should be made available to populations living within 200 miles of a nuclear power plant."

What is Potassium Iodide
In 1982 the FDA approved potassium iodide tablets as a thyroid-blocking agent for radiation exposure. In the event of nuclear disasters such as Fukushima and Chernobyl or fallout from a nuclear bomb, radioactive iodine (I-131), the predominant radionuclide created by nuclear fission, can travel thousands of miles downwind and cause thyroid cancer. The thyroid is the only organ that absorbs, stores and uses iodine. Potassium iodide, if stockpiled and administered daily as needed, can prevent the thyroid's absorption of the radioactive iodine by saturating the thyroid with safe, stable iodine.